Parameter
| Biomarker | PD-L1 | Full name | Programmed Death Ligand 1 | Molecular Type | Protein |
|---|---|---|---|---|---|
| Molecular Formula | / | Molecular Weight | / | Core Functional Dimensions | Prediction of immunotherapy efficacy |
| Disease | Small Cell Lung Cancer | Disease Subtypes | / | ||
| Organ | Lung | Test Sample / Technology Platform | Tumor tissue (specific technology platform not specified) | ||
| Pathobiological Mechanisms | PD-L1 binds to PD-1 on the surface of T cells and inhibits immune cell killing of tumor cells | ||||
| Clinical Availability Status | Study validation: predictive markers of immunotherapy efficacy | ||||
| Notes and Dynamics | The expression heterogeneity in the tumor tissues of SCLC patients was strong, with a positive expression rate of 10%-30%, and the detection platform and cutoff value standards were not unified | ||||